Anavex Life Sciences Corp: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Anavex Life Sciences Corp announces ANAVEX 3-71 highly effective and disease-modifying against all major Alzheimer's hallmarks in preclinical disease model
Anavex Life Sciences Corp:Says has unveiled promising preclinical data for ANAVEX 3-71 (formerly AF710B) in a presentation at the 2014 Alzheimer's Association International Conference (AAIC).Says data shows ANAVEX 3-71 to be disease modifying and highly effective in very small doses at countering the effects of major Alzheimer's hallmarks in a transgenic mouse model 3xTg-AD.Says those hallmarks include cognitive deficits, amyloid and tau pathologies, as well as neuroinflammation and mitochondrial dysfunctions.Reducing these major hallmarks has the potential to slow, stop or reverse Alzheimer's disease.Says ANAVEX 3-71 indicates extensive therapeutic advantages in Alzheimer's and other protein-aggregation-related diseases given its ability to enhance neuroprotection and cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation.
Latest Developments for Anavex Life Sciences Corp
- Anavex Life Sciences Corp announces positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for Treatment of Alzheimer's
- Anavex Life Sciences Corp Announces Changes In Registrant's Certifying Accountant
- Anavex Life Sciences Corp Raises $2.6 Million In Private Placement And appoints CEO
- Anavex Life Sciences Corp Announces Resignation Of President And Chief Financial Officer
- Share this
- Digg this